For details please refer to the section Investors/Financial Statements, Reports and Presentations
GUIDANCE

Note: The Guidance FY 2023 envisages the full consolidation of Blampin and Capexo as from Jan.1,2023. % chg. are calculated on median values.
(*) Excluding possible LTI/MBO to mature in 2022 and 2023 but including annual accruals of LTI matured in 2020 and 2021 .
(**) Excluding the increase in fixed assets due to the application of IFRS 16 but including ESG related investments.
FINANCIAL HIGHLIGHTS
Thousand of euro | 31.12.2021 | 31.12.2020 | 31.12.2019 |
Net sales | 1.069.776 | 1.041.535 | 1.005.718 |
Adjusted Ebitda* | 52.929 | 48.404 | 38.706 |
% Adjusted Ebitda | 4,9% | 4,6% | 3,8% |
Adjusted Ebit | 25.526 | 22.414 | 12.953 |
Ebit | 23.135 | 18.763 | 8.378 |
Profit/loss | 18.508 | 12.269 | 2.264 |
Adjusted profit/loss | 19.093 | 13.979 | 5.280 |
* Adjusted Ebitda: it’s determined by adding to the Operating Result (EBIT) the amounts for depreciation, amortization, and provisions, and excluding non-recurring costs/income and costs related to the Top management incentives |
Thousand of euro | 31.12.2021 | 31.12.2020 | 31.12.2019 |
Net Invested Capital | 260.199 | 263.423 | 277.830 |
Total Shareholders’ Equity | 175.186 | 160.111 | 150.931 |
Net Financial Position | 84.346 | 103.311 | 126.898 |
Financial Ratios: | |||
Net Financial Position/Total Shareholders’ Equity | 0,48 | 0,65 | 0,84 |
Net Financial Position/Adjusted Ebitda | 1,59 | 2,13 | 3,28 |